A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Key 1. Histologically or cytologically confirmed metastatic or locally advanced, squamous or non-squamous NSCLC (NSCLC). Patients must have received no more than four prior lines of therapy, including a PD-1 / PD-L1-containing therapy and a platinum containing regimen. Patients must have received no more than one taxane containing regimen and no more than one investigational agent; 2. Must provide study-related tumor specimens; 3. ECOG(PS) 0-1; 4. Estimated Life Expectancy \> 3 months; 5. Adequate bone marrow (BM), renal, hepatic and metabolic function. Key

1. Concurrent cancer treatment with cytoreductive therapy, radiotherapy, cytokine therapy, cytotoxic agents, targeted small molecule therapy or any investigational anticancer small molecule drugs within 2 weeks prior to the start of study treatment (except 5 weeks from last dose of nitrosourea compound) OR treatment with monoclonal antibodies within 4 weeks prior to the start of study treatment; 2. Known symptomatic central nervous system (CNS) metastases requiring steroids. 3. Diagnosis of any other malignancy within 2 years prior to enrollment; 4. Vaccination within 4 weeks of the first dose of study treatment is prohibited except for administration of inactivated vaccines; 5. Current use of immunosuppressive medication at study entry; 6. Active or prior autoimmune disease that might deteriorate with receiving an immunostimulatory agent; 7. Acute or chronic infections requiring systemic therapy; 8. Known history of autoimmune colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis; 9. Known intolerance to checkpoint inhibitor therapy, defined by the occurrence of an AE leading to drug discontinuation; 10. Participation in other studies involving investigational drug(s) within 28 days prior to study entry and/or during study participation.